**PRODUCT INFORMATION**

**Tasquinimod**  
*Item No. 17692*

**CAS Registry No.:** 254964-60-8  
**Formal Name:** 1,2-dihydro-4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-quinolinecarboxamide  
**Synonym:** ABR-215050  
**MF:** C$_{20}$H$_{17}$F$_{3}$N$_{2}$O$_{4}$  
**FW:** 406.4  
**Purity:** ≥98%  
**UV/Vis.:** $\lambda_{\text{max}}$: 232, 303 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly

**Laboratory Procedures**

Tasquinimod is supplied as a crystalline solid. A stock solution may be made by dissolving the tasquinimod in the solvent of choice. Tasquinimod is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of tasquinimod in these solvents is approximately 2, 10, and 20 mg/ml, respectively.

Tasquinimod is sparingly soluble in aqueous solutions. To enhance aqueous solubility, dilute the organic solvent solution into aqueous buffers or isotonic saline. If performing biological experiments, ensure the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. We do not recommend storing the aqueous solution for more than one day.

**Description**

Tasquinimod is an orally-active quinoline-3-carboxamide derived from roquinimex, an immunomodulatory quinolone with applications in some cancers and autoimmune diseases.\(^1\) Tasquinimod inhibits tumor angiogenesis and supplements radiation or chemotherapy in animal models of prostate cancer.\(^1,2\) While its precise mechanism of action remains unclear, tasquinimod has been reported to alter signaling through S100A9, thrombospondin-1, HIF-1α, androgen receptor, VEGF, and HDAC3/4.\(^1,2\)

**References**